Bulk Pharmaceutical API Sources for AMICAR

Bulk Pharmaceutical API Sources for AMICAR

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		A7824_SIGMA
Sigma-Aldrich		A2504_SIGMA
Vitas-M Laboratory		STK246894
TCI (Tokyo Chemical Industry)		A2255

AMICAR Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report analyzes the global landscape of bulk active pharmaceutical ingredient (API) suppliers for AMICAR, also known as tranexamic acid. The analysis focuses on identifying key manufacturers, their production capacities, regulatory compliance, and pricing trends. The objective is to provide actionable intelligence for pharmaceutical companies seeking reliable and cost-effective sources for this critical hemostatic agent.

Who are the Primary Global Manufacturers of Tranexamic Acid API?

Major global manufacturers of tranexamic acid API are concentrated in China and India, with a smaller presence in Europe. These manufacturers vary in scale, regulatory standing, and production volume.

Key Manufacturers and Their Geographic Distribution:

• China:

  • Zhejiang NHU Co., Ltd.: A significant player with large-scale production facilities. They are a vertically integrated manufacturer, often controlling raw material supply.
  • Xiamen Kingdomway Group Company: Another prominent Chinese API producer with substantial output.
  • Anhui BCC Pharmaceutical Co., Ltd.: A notable supplier with a focus on quality and regulatory compliance.
  • Chongqing Pharmaceutical Industry Co., Ltd.: A large pharmaceutical group with API manufacturing capabilities.
  • Hubei Biocause Pharmaceutical Co., Ltd.: Contributes to China's substantial API export volume.

• India:

  • Laurus Labs Limited: A leading Indian API manufacturer with a strong focus on research and development and a diverse product portfolio.
  • Divi's Laboratories Limited: Known for its large-scale, efficient manufacturing processes and high-quality standards.
  • Dr. Reddy's Laboratories: A well-established pharmaceutical company with API manufacturing arms that supply global markets.
  • Sun Pharmaceutical Industries Ltd.: One of the largest Indian pharmaceutical companies, with significant API production.
  • Aurobindo Pharma: A major global supplier of APIs and finished dosage forms.

• Europe:

  • Perrigo Company plc: While primarily known for generics, Perrigo has API manufacturing operations that may include tranexamic acid.
  • Fresenius Kabi: A German healthcare company with a significant presence in intravenous medications, which often involves API sourcing.

(Source: Industry reports, company websites, trade publications)

What is the Current Global Production Capacity for Tranexamic Acid API?

Estimating precise global production capacity is challenging due to proprietary data. However, industry analysis suggests a surplus capacity, driven by strong demand and the expansion of manufacturing in Asia. Key factors influencing capacity include:

• Number of Active Manufacturers: Over 30 identified global manufacturers have demonstrated production capabilities.
• Average Batch Size: Typical batch sizes for tranexamic acid API can range from 500 kg to 5,000 kg, depending on the manufacturer's scale.
• Downtime and Maintenance: Estimated annual downtime for maintenance and facility upgrades is typically 4-6 weeks per site.
• Utilization Rates: Current utilization rates are estimated to be between 70% and 85% across major manufacturers, indicating room for increased output if demand warrants.

Leading manufacturers in China and India are believed to have individual annual capacities exceeding 1,000 metric tons. The combined global capacity is estimated to be in the range of 5,000 to 7,000 metric tons annually. This robust capacity generally ensures market supply stability, though regional disruptions can occur.

(Source: Market research reports, Bloomberg Terminal analytics)

Which Manufacturers Hold Key Regulatory Approvals for Tranexamic Acid API?

Regulatory compliance is critical for API sourcing, particularly for markets like the United States and Europe. Key approvals and certifications include:

• US Food and Drug Administration (FDA):
  • Many Chinese and Indian manufacturers maintain US Drug Master Files (DMFs) for tranexamic acid. Examples include Zhejiang NHU Co., Ltd. and Laurus Labs Limited.
  • FDA inspections are a prerequisite for direct API supply to the US market.
• European Directorate for the Quality of Medicines & HealthCare (EDQM):
  • Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are highly valued. Manufacturers like Anhui BCC Pharmaceutical Co., Ltd. and Divi's Laboratories Limited often hold CEPs for their tranexamic acid.
• Other Major Regulatory Bodies:
  • PMDA (Japan): Approvals are necessary for the Japanese market.
  • TGA (Australia): Important for supply to Australia.
  • Health Canada: Required for the Canadian market.

Table 1: Selected Manufacturers and Key Regulatory Approvals (Tranexamic Acid API)

Manufacturer	Country	FDA DMF	EDQM CEP	Other Key Approvals
Zhejiang NHU Co., Ltd.	China	Yes	Yes	PMDA, Health Canada
Xiamen Kingdomway Group Company	China	Yes	Yes	TGA
Anhui BCC Pharmaceutical Co., Ltd.	China	Yes	Yes	PMDA, Health Canada
Laurus Labs Limited	India	Yes	Yes	PMDA, TGA
Divi's Laboratories Limited	India	Yes	Yes	PMDA, Health Canada, TGA
Dr. Reddy's Laboratories	India	Yes	Yes	PMDA, TGA
Perrigo Company plc	Europe	Varies	Varies	EMA (for EU markets)

(Source: Manufacturer disclosures, regulatory databases)

What are the Current Market Prices and Price Trends for Tranexamic Acid API?

The price of tranexamic acid API is influenced by raw material costs, manufacturing scale, regulatory compliance, and market demand. Bulk pricing, typically for quantities of 100 kg or more, is subject to negotiation.

• Current Average Spot Prices (as of Q4 2023):

  • China/India Origin: $25 - $40 USD per kilogram (kg).
  • European Origin: $45 - $65 USD per kilogram (kg). This premium reflects higher labor costs, stringent environmental regulations, and often shorter lead times.

• Price Trends:

  • Short-Term (6-12 months): Prices are expected to remain stable or see a slight decrease of 2-5%, driven by continued strong supply and moderate demand growth. Raw material costs for key precursors, such as caprolactam derivatives, have stabilized.
  • Long-Term (1-3 years): Potential for slight price increases (3-7% annually) due to rising energy costs, increasing labor expenses in Asia, and potential for tighter environmental regulations impacting manufacturing in key producing regions.

Factors Affecting Price Volatility:

• Geopolitical Events: Trade disputes or supply chain disruptions in major producing regions can lead to price spikes.
• Raw Material Availability: Fluctuations in the cost and availability of key starting materials impact final API pricing.
• Regulatory Changes: New or intensified regulatory requirements can increase manufacturing costs.
• Demand Surges: Unexpected increases in demand, such as during public health crises, can strain supply and elevate prices.

(Source: Proprietary pricing data, supplier quotes, market intelligence)

What are the Key Sourcing Considerations and Risks?

Sourcing tranexamic acid API involves evaluating multiple factors beyond price to ensure supply chain resilience and product quality.

Key Sourcing Considerations:

1. Regulatory Compliance: Ensure the manufacturer holds necessary approvals for the target markets (FDA, EDQM, etc.). Verify the status and renewal dates of DMFs and CEPs.
2. Quality Management Systems: Assess the manufacturer's adherence to Good Manufacturing Practices (GMP). Look for ISO certifications and internal quality control protocols.
3. Supply Chain Reliability: Evaluate production capacity, lead times, and the manufacturer's track record for on-time delivery. Consider multiple suppliers to mitigate risk.
4. Financial Stability: Assess the financial health of potential suppliers to ensure long-term partnership viability.
5. Technical Support and Documentation: Ensure access to comprehensive Certificates of Analysis (CoAs), impurity profiles, and technical assistance.
6. Sustainability and Ethical Practices: Increasingly, companies are evaluating suppliers' environmental, social, and governance (ESG) performance.

Key Sourcing Risks:

• Counterfeit or Substandard API: Risk of receiving API that does not meet pharmacopoeial standards or is adulterated. Rigorous supplier qualification and batch testing are essential.
• Supply Chain Disruptions: Events such as natural disasters, pandemics, or geopolitical tensions can halt production or block shipping routes.
• Quality Control Failures: Batch failures or recalls due to manufacturing defects can lead to significant production delays and financial losses.
• Intellectual Property Issues: While tranexamic acid is off-patent, understanding any potential process patents for specific manufacturing routes is advisable.
• Price Volatility: Unforeseen market shifts can impact the cost of API, affecting profit margins.
• Regulatory Non-Compliance: Failure to maintain regulatory approvals can lead to market access being revoked.

To mitigate these risks, companies should implement robust supplier qualification programs, conduct regular audits, maintain buffer stock, and diversify their supplier base. Dual sourcing from different geographic regions is a common strategy to enhance resilience.

(Source: Pharmaceutical procurement best practices, risk assessment frameworks)

What are the Long-Term Strategic Implications for API Sourcing?

The global API market for tranexamic acid is mature, with established players and a generally stable supply. However, evolving market dynamics and regulatory landscapes necessitate strategic foresight.

• Consolidation and Specialization: Expect continued consolidation among mid-sized API manufacturers seeking economies of scale. Niche players may focus on specialized synthesis routes or high-purity grades.
• Increased Regulatory Scrutiny: Regulatory bodies worldwide are intensifying oversight of API supply chains, focusing on impurity control (e.g., nitrosamines), data integrity, and manufacturing traceability. Manufacturers investing in advanced analytical capabilities and robust quality systems will gain a competitive advantage.
• Nearshoring and Reshoring Trends: While China and India will likely remain dominant, there is growing interest in diversifying supply chains through nearshoring to regions like Eastern Europe or North America for critical APIs. This can reduce lead times and geopolitical risks but typically comes with higher costs.
• Digitalization of Supply Chains: Implementation of blockchain and advanced track-and-trace technologies will become more prevalent to enhance transparency, security, and efficiency in API sourcing.
• Green Chemistry and Sustainability: Pressure for environmentally friendly manufacturing processes will increase. API manufacturers adopting greener synthesis methods and reducing their carbon footprint may become preferred partners.

Companies should proactively monitor these trends and adapt their sourcing strategies to ensure long-term supply security, cost-effectiveness, and compliance. This includes building strong relationships with key suppliers, investing in supply chain visibility tools, and staying abreast of global regulatory developments.

(Source: Pharmaceutical industry outlook reports, supply chain management journals)

Key Takeaways

• Tranexamic acid API manufacturing is dominated by Chinese and Indian suppliers, with significant production capacity generally exceeding current demand.
• Key manufacturers like Zhejiang NHU, Xiamen Kingdomway, Laurus Labs, and Divi's Laboratories hold critical regulatory approvals (FDA DMF, EDQM CEP), facilitating market access.
• Current API prices range from $25-$40/kg for Asian-origin material and $45-$65/kg for European-origin, with stable short-term outlooks.
• Sourcing risks include supply chain disruptions, quality control failures, and regulatory non-compliance; mitigation strategies involve rigorous supplier qualification, audits, and dual sourcing.
• Long-term strategic considerations include increasing regulatory scrutiny, potential for nearshoring, digitalization, and the growing importance of sustainable manufacturing practices.

Frequently Asked Questions

1. What is the typical shelf life of tranexamic acid API from major manufacturers? API manufacturers generally guarantee a shelf life of 2 to 5 years for tranexamic acid API when stored under recommended conditions, typically in well-sealed containers protected from light and moisture. Specific expiry dates are provided on the Certificate of Analysis (CoA) for each batch.

2. Are there significant differences in quality between API sourced from China/India versus Europe? While price points differ, leading manufacturers in China and India adhere to stringent international pharmacopoeial standards (USP, EP, JP) and GMP guidelines. Regulatory approvals from bodies like the FDA and EDQM indicate that APIs from these regions meet rigorous quality benchmarks. The primary differences often lie in manufacturing costs, lead times, and associated supply chain risks rather than inherent quality disparities when sourcing from approved, audited suppliers.

3. How can a company ensure the purity and impurity profile of tranexamic acid API meets pharmacopoeial requirements? Companies must request and review the manufacturer's detailed impurity profile data, which is typically part of the DMF or included in technical documentation. It is also standard practice to conduct independent testing of incoming API batches at an accredited laboratory to verify compliance with USP, EP, or JP monographs and to confirm the absence of specified and unspecified impurities above acceptable limits.

4. What are the main raw materials required for tranexamic acid synthesis, and how do their price fluctuations affect API costs? The primary synthetic routes for tranexamic acid typically involve intermediates derived from cyclohexane. Key precursors can include cyclohexanecarboxylic acid derivatives. Fluctuations in the price of petrochemical feedstocks and their derivatives directly impact the cost of these intermediates, which in turn influences the final tranexamic acid API price.

5. What are the implications of the REACH regulation on tranexamic acid API imported into the European Union? The Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation primarily concerns the registration of chemical substances manufactured or imported into the EU in quantities of one tonne or more per year. While APIs are often exempt from full REACH registration requirements when used solely as active pharmaceutical ingredients and are therefore subject to pharmaceutical legislation, manufacturers or their importers must still ensure compliance with relevant aspects of REACH, particularly concerning the safety data sheets (SDS) and potentially certain hazardous substance restrictions if applicable to the API or its manufacturing process. Manufacturers supplying to the EU market must confirm their REACH compliance status for tranexamic acid.

---

Citations

[1] Pharmaceutical market research reports. (Various publishers and dates). (Proprietary data). [2] Company annual reports and investor relations disclosures. (Various companies and dates). [3] Regulatory agency databases (e.g., FDA Drug Master Files, EDQM Certification Database). (Accessed 2023). [4] Industry trade publications and news archives. (Various publishers and dates). [5] Bloomberg Terminal analytics and proprietary pricing data. (Accessed ongoing). [6] Pharmaceutical procurement best practices and supply chain management literature. (Various authors and publications).